A randomized, double-blind trial comparing the efficacy and safety of a fixed combination of fenofibrate and metformin vs rosiglitazone in patients with type 2 diabetes mellitus and dyslipidemia.

Trial Profile

A randomized, double-blind trial comparing the efficacy and safety of a fixed combination of fenofibrate and metformin vs rosiglitazone in patients with type 2 diabetes mellitus and dyslipidemia.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 01 Jun 2011

At a glance

  • Drugs Fenofibrate/metformin; Rosiglitazone
  • Indications Dyslipidaemias; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms FAME-ROSI
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 27 Apr 2010 Trial sponsor, affiliate changed from Solvay Pharmaceuticalsto Abbott labs as reported by ClinicalTrials.gov.
    • 26 Jun 2008 Actual end date (Mar 2007) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top